ArticleBioMed research international2018
Effects of Propranolol on Neurodevelopmental Outcomes in Patients with Infantile Hemangioma: A Case-Control Study.
Article in BioMed research international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 21 citations in OpenAlex.
- Neurodevelopmental Effects of Propranolol Treatment During Infancy in Infantile Hemangioma Patients.Children (Basel, Switzerland) · 2024Article
- Decreased wrist rotation imitation abilities in children with autism spectrum disorder.Frontiers in psychiatry · 2024Article
- Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma.European journal of pediatrics · 2023Article
- Association between maternal parenting styles and behavioral problems in children with ASD: Moderating effect of maternal autistic traits.Frontiers in psychiatry · 2023Article
- Propranolol for Treatment of Infantile Hemangioma: Efficacy and Effect on Pediatric Growth and Development.International journal of pediatrics · 2021Article
- Correlation Between Screen Time and Autistic Symptoms as Well as Development Quotients in Children With Autism Spectrum Disorder.Frontiers in psychiatry · 2021Article
- Paediatrics: how to manage infantile haemangioma.Drugs in context · 2021Review
- Progress in the treatment of infantile hemangioma.Annals of translational medicine · 2019Review
- Outcomes of surgical treatment for hemangiomas.Pediatric dermatology · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study was to examine whether oral propranolol has any effect on neurodevelopment outcomes in young children with problematic infantile hemangiomas (IHs).
methodsThirty-six children with a diagnosis of problematic IH who were treated with oral propranolol were compared with 34 healthy children with no history of propranolol therapy. Patients received propranolol therapy for at least 3 months. Gesell developmental schedules (GDS) were used to evaluate neurodevelopment outcomes in the two groups. The scores of each GDS domain were compared between the two groups.
resultsThere were no significant differences in developmental quotient (DQ) values for any of the five domains between the patients and healthy controls (
conclusionPropranolol has no obvious effect on neurodevelopmental outcomes in children. Early treatment and treatment duration had no negative effect on central nervous system (CNS) development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.